PARP1 and neoplasm: In summary, these data provide supportive preclinical data that inhibiting topoisomerase I and PARP1 in combination, as was demonstrated with the combination of ABT-888 and CPT-11, may result in synergistic decreases in tumor regression for women with TNBC.